HALO expands collaboration and licensing deal with ARGX for ENHANZE technology
FROM THE WIRE · FINANCE.YAHOO.COM
Halozyme Therapeutics HALO announced that it has expanded the global collaboration and license agreement with argenx ARGX to develop and commercialize its ENHANZE technology with two additional exclusive targets. The expanded collaboration builds on the companies' existing…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishHalozyme and argenx expand partnership to develop ENHANZE with two additional targets, positive for both companies.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Halozyme expanded global collaboration and license agreement with argenx to develop ENHANZE with two additional exclusive targets.
- 02Expanded agreement increases argenx's exclusive access to ENHANZE from six to eight targets.
- 03Halozyme eligible to receive milestone payments and royalties on net sales of products developed using ENHANZE.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Halozyme Therapeutics, Inc.111.33 USD+0.71%today +1.46%Positive argenx SE940.72 USD+0.59%today +1.10%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets